Foundation Medicine, Inc. Discovers High Incidence of Clinically Actionable ERBB2 (HER2) Alterations In Aggressive Form Of Bladder Cancer; Data Published In Clinical Cancer Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced the discovery of a high incidence of ERBB2 (HER2) extracellular domain alterations in patients with micropapillary urothelial carcinoma (MPUC), a particularly aggressive form of urinary bladder cancer, using FoundationOne™. The research was published in the current edition of Clinical Cancer Research1.

Help employers find you! Check out all the jobs and post your resume.